Wuhan Easy Diagnosis Biomedicine Co.,Ltd. (SHE:002932)
China flag China · Delayed Price · Currency is CNY
14.46
-0.02 (-0.14%)
Nov 13, 2026, 3:04 PM CST

SHE:002932 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-63.95-16.4674.5274.934,2081,413
Depreciation & Amortization
54.3854.3862.9883.459.0823.63
Other Amortization
1.021.0214.5111.822.650.87
Loss (Gain) From Sale of Assets
-0.66-0.66-1.79-0.31-0.01-
Asset Writedown & Restructuring Costs
78.3578.3591.01-4.58646.5621.33
Loss (Gain) From Sale of Investments
-103.96-103.96-135.44-125.14-37.88-0.67
Other Operating Activities
41.7-56.65-47.283.29153.3334.62
Change in Accounts Receivable
176.21176.21411.721,256-2,325-722.32
Change in Inventory
35.3135.3184.76342.82-473.38-166.86
Change in Accounts Payable
-244.39-244.39-644.14-1,3021,539530.21
Change in Other Net Operating Assets
---79.95370.01-
Operating Cash Flow
-19.19-70.05-85.05392.54,0131,127
Operating Cash Flow Growth
----90.22%256.06%213.33%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-55.51-90.89-184.77-109.97-313.38-103.57
Sale of Property, Plant & Equipment
2.544.170.780.15--
Divestitures
0.840.84----
Investment in Securities
305.61449.6528.04-1,290-1,958-588
Other Investing Activities
277.6766.1517.8234.7137.186.45
Investing Cash Flow
384.06429.91-138.12-1,365-2,234-685.12

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
--323.61137.3930
Long-Term Debt Issued
-1.9518.88---
Total Debt Issued
17.531.9521.8823.61137.3930
Short-Term Debt Repaid
--3-23.61-125-53.42-141.5
Long-Term Debt Repaid
--3.45-6-20.49-4.72-2.95
Lease Payments
-3.45-3.45-6-20.49-4.72-2.95
Total Debt Repaid
-8.46-6.45-29.61-145.49-58.14-144.45
Net Debt Issued (Repaid)
9.08-4.49-7.74-121.8779.24-114.45
Issuance of Common Stock
-----482.71
Repurchase of Common Stock
--10.01-238.16-0.53--
Common Dividends Paid
-0.26-263.26-34.19-582.48-550.64-283.39
Other Financing Activities
-178.65-6.59-33.0834.8338.6-2.6
Financing Cash Flow
-169.83-284.35-313.17-670.06-432.7982.27

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-6.69-1.550.511.2619.47-3.2
Net Cash Flow
188.3473.95-535.83-1,6411,365520.96

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-74.7-160.95-269.81282.523,6991,023
Free Cash Flow Growth
----92.36%261.47%208.82%
Free Cash Flow Margin
-23.39%-60.72%-77.08%37.69%35.13%36.17%
Free Cash Flow Per Share
-0.33-0.68-1.201.2416.094.84
Levered Free Cash Flow
--225.37-178.98384.352,660631.65
Unlevered Free Cash Flow
--225.09-178.17390.912,662632.97
Free Cash Flow After Leases
-78.15-164.39-275.81262.043,6951,020

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
29.2714.774.45268.91,253219.86
Change in Working Capital
-26.07-26.07-143.56349.09-1,019-365.99